PSMB9 Codon 60 Polymorphisms Have No Impact on the Activity of the Immunoproteasome Catalytic Subunit B1i Expressed in Multiple Types of Solid Cancer

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Park, Ji Eun ^a   Ao, Lin ^a   Miller, Zachary ^a   Kim, Kyungbo ^a   Wu, Ying ^a   Jang, Eun Ryoung ^a   Lee, Eun Young ^b   Kim, Kyung Bo ^a   Lee, Wooin ^a  

^a University of Kentucky   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOPROTEASOME CATALYTIC SUBUNIT B1I; PROTEASOME; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CODON; COLON CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; GENE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOLECULAR PATHOLOGY; PANCREAS CANCER; PROTEIN EXPRESSION; PSMB9 GENE; SOLID TUMOR;

AMINO ACID SUBSTITUTION; BIOCATALYSIS; CATALYTIC DOMAIN; CELL LINE, TUMOR; CODON; COLONIC NEOPLASMS; CYSTEINE ENDOPEPTIDASES; FLUORESCENT DYES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HCT116 CELLS; HUMANS; HYDROLYSIS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MCF-7 CELLS; NEOPLASMS; PANCREATIC NEOPLASMS; POLYMORPHISM, GENETIC; TISSUE ARRAY ANALYSIS;

EID: 84883641810     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073732     Document Type: Article

References (34)

1. Petroski MD, (2008) The ubiquitin system, disease, and drug discovery. BMC Biochem 9Suppl 1: S7.
2. Marques AJ, Palanimurugan R, Matias AC, Ramos PC, Dohmen RJ, (2009) Catalytic mechanism and assembly of the proteasome. Chem Rev 109: 1509-1536.
3. Mishto M, Santoro A, Bellavista E, Bonafe M, Monti D, et al. (2003) Immunoproteasomes and immunosenescence. Ageing Res Rev 2: 419-432.
4. Fruh K, Gossen M, Wang K, Bujard H, Peterson PA, et al. (1994) Displacement of housekeeping proteasome subunits by MHC-encoded LMPs: a newly discovered mechanism for modulating the multicatalytic proteinase complex. Embo J 13: 3236-3244.
5. Piccinini M, Mostert M, Croce S, Baldovino S, Papotti M, et al. (2003) Interferon-gamma-inducible subunits are incorporated in human brain 20 S proteasome. J Neuroimmunol 135: 135-140.
6. Louie JL, Kapphahn RJ, Ferrington DA, (2002) Proteasome function and protein oxidation in the aged retina. Exp Eye Res 75: 271-284.
7. Miller Z, Ao L, Kim KB, Lee W (2013) Inhibitors of the Immunoproteasome: Current Status and Future Directions. Curr Pharm Des (In press).
8. Faucz FR, Probst CM, Petzl-Erler ML, (2000) Polymorphism of LMP2, TAP1, LMP7 and TAP2 in Brazilian Amerindians and Caucasoids: implications for the evolution of allelic and haplotypic diversity. Eur J Immunogenet 27: 5-16.
9. Lichter DI, Danaee H, Pickard MD, Tayber O, Sintchak M, et al. (2012) Sequence analysis of beta-subunit genes of the 20 S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. Blood.
10. Vargas-Alarcon G, Gamboa R, Vergara Y, Rodriguez-Zepeda JM, de la Pena A, et al. (2002) LMP2 and LMP7 gene polymorphism in Mexican populations: Mestizos and Amerindians. Genes Immun 3: 373-377.
11. Maksymowych WP, Tao S, Vaile J, Suarez-Almazor M, Ramos-Remus C, et al. (2000) LMP2 polymorphism is associated with extraspinal disease in HLA-B27 negative Caucasian and Mexican Mestizo patients with ankylosing spondylitis. J Rheumatol 27: 183-189.
12. Heward JM, Allahabadia A, Sheppard MC, Barnett AH, Franklyn JA, et al. (1999) Association of the large multifunctional proteasome (LMP2) gene with Graves' disease is a result of linkage disequilibrium with the HLA haplotype DRB1*0304-DQB1*02-DQA1*0501. Clin Endocrinol (Oxf) 51: 115-118.
13. Vinasco J, Fraile A, Nieto A, Beraun Y, Pareja E, et al. (1998) Analysis of LMP and TAP polymorphisms by polymerase chain reaction- restriction fragment length polymorphism in rheumatoid arthritis. Ann Rheum Dis 57: 33-37.
14. Deng GY, Muir A, Maclaren NK, She JX, (1995) Association of LMP2 and LMP7 genes within the major histocompatibility complex with insulin-dependent diabetes mellitus: population and family studies. Am J Hum Genet 56: 528-534.
15. Mishto M, Bellavista E, Ligorio C, Textoris-Taube K, Santoro A, et al. (2010) Immunoproteasome LMP2 60 HH variant alters MBP epitope generation and reduces the risk to develop multiple sclerosis in Italian female population. PloS one 5: e9287.
16. Goncharov SV, Dosenko VE, Haitovich NV, Moibenko AA, (2009) [Allele polymorphism of genes coding proteasome subunits is associated with an enhanced risk for arterial hypertension in adolescents]. Fiziol Zh 55: 3-10.
17. Mishto M, Bellavista E, Santoro A, Stolzing A, Ligorio C, et al. (2006) Immunoproteasome and LMP2 polymorphism in aged and Alzheimer's disease brains. Neurobiol Aging 27: 54-66.
18. Mishto M, Santoro A, Bellavista E, Sessions R, Textoris-Taube K, et al. (2006) A structural model of 20 S immunoproteasomes: effect of LMP2 codon 60 polymorphism on expression, activity, intracellular localisation and insight into the regulatory mechanisms. Biol Chem 387: 417-429.
19. Lin G, Tsu C, Dick L, Zhou XK, Nathan C, (2008) Distinct specificities of Mycobacterium tuberculosis and mammalian proteasomes for N-acetyl tripeptide substrates. J Biol Chem 283: 34423-34431.
20. Blackburn C, Gigstad KM, Hales P, Garcia K, Jones M, et al. (2010) Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20 S beta5-subunit. Biochemical J 430: 461-476.
21. Ho YK, Bargagna-Mohan P, Wehenkel M, Mohan R, Kim KB, (2007) LMP2-specific inhibitors: chemical genetic tools for proteasome biology. Chem Biol 14: 419-430.
22. Kim KB, Fonseca FN, Crews CM, (2005) Development and characterization of proteasome inhibitors. Methods Enzymol 399: 585-609.
23. Wehenkel M, Ban JO, Ho YK, Carmony KC, Hong JT, et al. (2012) A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice. Br J Cancer 107: 53-62.
24. Mishto M, Bonafe M, Salvioli S, Olivieri F, Franceschi C, (2002) Age dependent impact of LMP polymorphisms on TNFalpha-induced apoptosis in human peripheral blood mononuclear cells. Exp Gerontol 37: 301-308.
25. Jang ER, Lee NR, Han S, Wu Y, Sharma LK, et al. (2012) Revisiting the role of the immunoproteasome in the activation of the canonical NF-kappaB pathway. Mol Biosyst 8: 2295-2302.
26. Kuhn DJ, Orlowski RZ, (2012) The immunoproteasome as a target in hematologic malignancies. Semin Hematol 49: 258-262.
27. Singh AV, Bandi M, Aujay MA, Kirk CJ, Hark DE, et al. (2011) PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo. Br J Haematol 152: 155-163.
28. Imanishi T, Kamigaki T, Nakamura T, Hayashi S, Yasuda T, et al. (2006) Correlation between expression of major histocompatibility complex class I and that of antigen presenting machineries in carcinoma cell lines of the pancreas, biliary tract and colon. Kobe J Med Sci 52: 85-95.
29. Kang JK, Yoon SJ, Kim NK, Heo DS, (2000) The expression of MHC class I, TAP1/2, and LMP2/7 gene in human gastric cancer cell lines. Int J Oncol 16: 1159-1163.
30. Liu Q, Hao C, Su P, Shi J, (2009) Down-regulation of HLA class I antigen-processing machinery components in esophageal squamous cell carcinomas: association with disease progression. Scand J Gastroenterol 44: 960-969.
31. Murakami Y, Kanda K, Yokota K, Kanayama H, Kagawa S, (2001) Prognostic significance of immuno-proteosome subunit expression in patients with renal-cell carcinoma: a preliminary study. Mol Urol 5: 113-119.
32. Meidenbauer N, Zippelius A, Pittet MJ, Laumer M, Vogl S, et al. (2004) High frequency of functionally active Melan-a-specific T cells in a patient with progressive immunoproteasome-deficient melanoma. Cancer Res 64: 6319-6326.
33. Ritz U, Momburg F, Pilch H, Huber C, Maeurer MJ, et al. (2001) Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. Int J Oncol 19: 1211-1220.
34. Meissner M, Reichert TE, Kunkel M, Gooding W, Whiteside TL, et al. (2005) Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res 11: 2552-2560.